![](/img/cover-not-exists.png)
Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
Zwitter, Matjaz, Stanic, Karmen, Rajer, Mirjana, Kern, Izidor, Vrankar, Martina, Edelbaher, Natalija, Kovac, ViljemVolume:
48
Language:
english
Journal:
Radiology and Oncology
DOI:
10.2478/raon-2014-0038
Date:
January, 2014
File:
PDF, 646 KB
english, 2014